Posted by Michael Wonder on 19 May 2022
BMS’ Sprycel reimbursement criteria to be broadened for paediatric Philadelphia chromosome positive ALL
19 May 2022 - The state health insurance review agency said it would broaden the reimbursement criteria for Sprycel (dasatinib), a leukaemia treatment by Bristol-Myers Squibb.
On Wednesday, HIRA released the review results on cancer drug reimbursement criteria.
